Advertisement
Canada markets open in 5 hours 10 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7267
    +0.0003 (+0.05%)
     

  • CRUDE OIL

    83.03
    +0.30 (+0.36%)
     

  • Bitcoin CAD

    89,439.12
    +5,559.87 (+6.63%)
     

  • CMC Crypto 200

    1,328.33
    +15.70 (+1.20%)
     

  • GOLD FUTURES

    2,396.80
    -1.20 (-0.05%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,415.75
    -131.50 (-0.75%)
     

  • VOLATILITY

    20.34
    +2.34 (+13.01%)
     

  • FTSE

    7,830.86
    -46.19 (-0.59%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

Greenbrook TMS Announces Dates for Its First Quarter 2023 Financial Results

Business Wire
·2 min read

TORONTO, May 10, 2023--(BUSINESS WIRE)--Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company"), will release its 2023 first quarter operational and financial results after market hours on May 15, 2023.

FIRST QUARTER 2023 CONFERENCE CALL DETAILS:

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on May 16, 2023 to discuss the financial results for the quarter.

Dial in Numbers:

Toll Free North America: 1 (888) 886-7786
Toronto: (416) 764-8658

Webcast:

For more information or to listen to the call via webcast, please visit:
www.greenbrooktms.com/investors/events.htm

ADVERTISEMENT

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Conference Call Replay:

Following the live call, a replay will be available on the Investor Relations section of the Company’s website, www.greenbrooktms.com/investors/events.htm

About Greenbrook TMS Inc.

Operating through 133 Company-operated treatment centers (following completion of the Company’s previously-announced restructuring plan), Greenbrook is a leading provider of Transcranial Magnetic Stimulation ("TMS") and Spravato® (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder ("MDD") and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than one million treatments to over 30,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006037/en/

Contacts

For further information please contact:

Glen Akselrod
Investor Relations
Greenbrook TMS Inc.

Contact Information:
investorrelations@greenbrooktms.com
1-855-797-4867